|
|
|
| Research advances of Anlotinib in the treatment of advanced none-small cell lung cancer |
| XIA Bo CHENG Zhixiang |
| Department of Pain Management, the Second Affiliated Hospital, Nanjing Medical University, Jiangsu Province, Nanjing 210011, China |
|
|
|
Abstract Angiogenesis is an important segment in the process of multiplication, invasion, and metastasis of malignant tumor cells. Anti-angiogenic drug plays an important role in the treatment of cancer. Anlotinib is a new small molecule multi-target anti-angiogenesis drug tyrosine kinase inhibitor developed independently in China. It can effectively inhibit such as vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor, c-kitproto-oncogeneprotein and so on to completely block tumor angiogenesis and inhibit tumor growth with low toxic and side effects. Several clinical trials confirm that Anlotinib has promising efficacy and safety in advanced non-small cell lung cancer. This paper summarizes the current knowledge of Anlotinib in anti-tumor mechanism, clinical efficacy and safety studies, efficacy predictive factors, and drug resistance mechanism in recent years.
|
|
|
|
|
|
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Liu Q，Luo X，Peng L，et al. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China：A Cost-Effectiveness Analysis [J]. Clin Drug Investig，2020，40（2）：129-137.
[3] Nicosia RF，Tchao R，Leighton J. Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture [J]. Clin Exp Metastasis，1986，4（2）：91-104.
[4] Bielenberg DR，Zetter BR. The Contribution of Angiogenesis to the Process of Metastasis [J]. Cancer J，2015，21（4）：267-273.
[5] Jayson GC，Kerbel R，Ellis LM，et al. Antiangiogenic therapy in oncology：current status and future directions [J]. Lancet，2016，388（10043）：518-529.
[6] Li J，Zhou N，Luo K，et al. In Silico Discovery of Potential VEGFR-2 Inhibitors from Natural Derivatives for Anti-Angiogenesis Therapy [J]. Int J Mol Sci，2014，15（9）：15994-16011.
[7] Syed YY. Anlotinib：First Global Approval [J]. Drugs，2018，78（10）：1057-1062.
[8] Yu L，Chen Y，Tooze SA. Autophagy pathway：Cellular and molecular mechanisms [J]. Autophagy，2018，14（2）：207-215.
[9] Xie C，Wan X，Quan H，et al. Preclinical characterization of anlotinib，a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor [J]. Cancer Sci，2018，109（4）：1207-1219.
[10] Touat M，Ileana E，Postel-Vinay S，et al. Targeting FGFR Signaling in Cancer [J]. Clin Cancer Res，2015，21（12）：2684-2694.
[11] Babina IS，Turner NC. Advances and challenges in targeting FGFR signalling in cancer [J]. Nat Rev Cancer，2017，17（5）：318-332.
[12] Mulligan LM. RET revisited：expanding the oncogenic portfolio [J]. Nat Rev Cancer，2014，14（3）：173-186.
[13] Abbaspour Babaei M，Kamalidehghan B，Saleem M，et al. Receptor tyrosine kinase（c-Kit）inhibitors：a potential therapeutic target in cancer cells [J]. Drug Des Devel Ther，2016，10：2443-2459.
[14] Szturz P，Raymond E，Abitbol C，et al. Understanding c-MET signalling in squamous cell carcinoma of the head & neck [J]. Crit Rev Oncol Hematol，2017，111：39-51.
[15] Lin B，Song X，Yang D，et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2，PDGFRbeta and FGFR1 [J]. Gene，2018，654：77-86.
[16] Han B，Li K，Zhao Y，et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer：a multicentre，randomised phase Ⅱ trial（ALTER0302）[J] . Br J Cancer，2018，118（5）：654661．
[17] Han B，Li K，Wang Q，et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer：The ALTER 0303 Phase 3 Randomized Clinical Trial [J]. JAMA Oncol，2018，4（11）：1569-1575.
[18] Wang L，He Z，Yang S，et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer （NSCLC）：a subgroup analysis of ALTER0303 trial [J]. Transl Lung Cancer Res，2019，8（5）：575-583.
[19] Jiang S，Liang H，Liu Z，et al. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer：Post Hoc Analysis of a Phase Ⅲ Randomized Control Trial（ALTER0303）[J]. Oncologist，2020，25（5）：e870-e874.
[20] Si X，Zhang L，Wang H，et al. Quality of life results from a randomized，double-blinded，placebo-controlled，multi-center phase Ⅲ trial of anlotinib in patients with advanced non-small cell lung cancer [J]. Lung Cancer，2018，122：32-37.
[21] Wu D，Nie J，Dai L，et al. Salvage treatment with anlotinib for advanced non-small cell lung cancer [J]. Thorac Cancer，2019，10（7）：1590-1596.
[22] Wang J，Zhao Y，Wang Q，et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment [J]. Cancer Biol Med，2018，15（4）：443-451.
[23] Liu Z，Wang J，Meng Z，et al. CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer：Analysis on ALTER-0303 study [J]. Cancer Med，2018，7（7）：30113021.
[24] Lu J，Xu W，Qian J，et al. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells [J]. BMC Medical Genom，2019，12（Suppl 2）：38.
[25] Lu J，Zhong H，Wu J，et al. Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer [J]. Adv Sci（Weinh），2019，6（19）：1900721.
[26] Liang L，Hui K，Hu C，et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells [J]. J Exp Clin Cancer Res，2019，38（1）：71.
[27] Lu J，Zhong H，Chu T，et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy [J]. Eur Respir J，2019，53（3）：1801562. |
|
|
|
